In a Thursday report, analyst Andrew Chow says, “While earnings outlook for the next two years will likely be crimped by start-up losses in China, we believe growth over the next 10 years will be significantly enhanced where capacity will more than quadruple.”
SINGAPORE (Sept 21): UOB Kay Hian is upgrading its call on Raffles Medical Group (RMG) to “buy” from “hold” with a target price of $1.28.
To recap, since UOB Kay Hian downgraded the group to “hold” in April, its shares have declined about 22%.
